Cumberland Pharmaceuticals Q2 adjusted EPS USD -0.2

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported an adjusted earnings loss of $0.20 per diluted share for the second quarter of 2026, according to its recent financial results. This represents a decline compared to adjusted earnings of $0.18 per diluted share in the same period in 2025.

The company's net revenues for the second quarter of 2026 were $10.8 million, reflecting a 10% increase compared to the second quarter of 2025. Year-to-date revenues for the first six months of 2026 totaled $22.6 million, a 23% increase compared to the first half of 2024.

Operating expenses for the second quarter of 2026 were $11.6 million, while total operating expenses reached $22 million for the first half of the year. The company reported a net loss of approximately $741,000 for the second quarter and a net income of approximately $516,000 for the first six months of 2026.

Cumberland Pharmaceuticals ended the second quarter of 2026 with approximately $68 million in total assets, $40 million in liabilities, and $28 million in shareholders' equity. The company's cash and cash equivalents stood at $16 million as of June 30, 2026.

The company's adjusted earnings loss for the second quarter of 2026 reflects income taxes, depreciation and amortization expenses, share-based compensation, interest income, and interest expenses. Despite the adjusted loss, Cumberland Pharmaceuticals continues to focus on its clinical development programs and strategic initiatives to drive long-term growth.